These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17567730)

  • 21. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
    Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
    Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of mouse small intestinal cytochrome P450 expression.
    Zhang QY; Dunbar D; Kaminsky LS
    Drug Metab Dispos; 2003 Nov; 31(11):1346-51. PubMed ID: 14570766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
    Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
    Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
    Huang Z; Raychowdhury MK; Waxman DJ
    Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
    Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
    J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of bioavailability of experimental controlled release microcapsules of nifedipine.
    Mallick S; Gupta BK; Ghosal SK
    Acta Pol Pharm; 2000; 57(3):175-80. PubMed ID: 11143705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine.
    Hashizume T; Mise M; Matsumoto S; Terauchi Y; Fujii T; Imaoka S; Funae Y; Kamataki T; Miyazaki H
    Drug Metab Dispos; 2001 Jun; 29(6):798-805. PubMed ID: 11353747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse.
    Zhu Y; D'Agostino J; Zhang QY
    Drug Metab Dispos; 2011 Jun; 39(6):939-43. PubMed ID: 21349922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of nifedipine metabolism in dogs by erythromycin: difference between the gut wall and the liver.
    Tsuruta S; Nakamura K; Arimori K; Nakano M
    J Pharm Pharmacol; 1997 Dec; 49(12):1205-10. PubMed ID: 9466344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity.
    Xue X; Gong L; Qi X; Wu Y; Xing G; Yao J; Luan Y; Xiao Y; Li Y; Wu X; Chen M; Gu J; Ren J
    Toxicol Lett; 2011 Aug; 205(1):47-54. PubMed ID: 21596114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey.
    Nishimura T; Amano N; Kubo Y; Ono M; Kato Y; Fujita H; Kimura Y; Tsuji A
    Drug Metab Dispos; 2007 Aug; 35(8):1275-84. PubMed ID: 17470527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lung injury induced by pyrrolizidine alkaloids depends on metabolism by hepatic cytochrome P450s and blood transport of reactive metabolites.
    He Y; Lian W; Ding L; Fan X; Ma J; Zhang QY; Ding X; Lin G
    Arch Toxicol; 2021 Jan; 95(1):103-116. PubMed ID: 33033841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
    Press RR; Buckle T; Beijnen JH; van Tellingen O
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circadian variations in the pharmacokinetics, tissue distribution and urinary excretion of nifedipine after a single oral administration to rats.
    Cao QR; Kim TW; Choi JS; Lee BJ
    Biopharm Drug Dispos; 2005 Dec; 26(9):427-37. PubMed ID: 16217814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of mouse hepatic CYP3A protein by 3-methylcholanthrene does not require cytochrome P450-dependent metabolism.
    Lee C; Ding X; Riddick DS
    Drug Metab Dispos; 2013 Oct; 41(10):1782-6. PubMed ID: 23846873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic interactions of nifedipine and quinidine.
    Hippius M; Henschel L; Sigusch H; Tepper J; Brendel E; Hoffmann A
    Pharmazie; 1995 Sep; 50(9):613-6. PubMed ID: 7480098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog and human.
    Teramura T; Watanabe T; Higuchi S; Hashimoto K
    Xenobiotica; 1995 Nov; 25(11):1237-46. PubMed ID: 8592872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application.
    Wong H; Grossman SJ; Bai SA; Diamond S; Wright MR; Grace JE; Qian M; He K; Yeleswaram K; Christ DD
    Drug Metab Dispos; 2004 Dec; 32(12):1359-69. PubMed ID: 15333515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study.
    Wonnemann M; Schug B; Anschütz M; Brendel E; De Nucci G; Blume H
    Clin Ther; 2008 Jan; 30(1):48-58. PubMed ID: 18343242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats.
    Choi JS; Choi I; Choi DH
    Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):231-8. PubMed ID: 25549928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.